A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

AG Ken Paxton pushed debunked misinformation about COVID-19 vaccines. What a shame the damage can’t be undone as easily as ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...

Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...

From condemning the Jan. 6 Capitol riots to helping fund the President-elect’s impending inauguration, recent years have seen ...